Photocure ASA Logo

Photocure ASA

Develops photodynamic pharmaceuticals and devices to enhance bladder cancer detection for urologists.

PHO | OL

Overview

Corporate Details

ISIN(s):
NO0010000045
LEI:
5967007LIEEXZXG8OW35
Country:
Norway
Address:
HOFFSVEIEN 4, 0275 OSLO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Photocure ASA is a specialty pharmaceutical company, self-described as 'The Bladder Cancer Company.' It develops and commercializes pharmaceuticals and medical devices based on its proprietary photodynamic technology platform. The company's core focus is on improving the diagnosis, treatment, and management of bladder cancer. Its flagship products, marketed as Hexvix® and Cysview®, are used in conjunction with Blue Light Cystoscopy to enhance the visualization and detection of cancerous tumors. Photocure targets the global urologic oncology community, including hospitals, clinics, and specialists, providing transformative solutions to improve patient outcomes.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-22 08:23
Director's Dealing
Photocure ASA - Share option grant - Attachment: 20250922_PHO_Primary_insider_n…
English 110.6 KB
2025-09-22 08:23
Remuneration Information
Photocure ASA - Share option grant - Attachment: Release.pdf
English 136.2 KB
2025-09-22 08:23
Remuneration Information
Photocure ASA - Share option grant
English 2.7 KB
2025-08-04 14:39
Regulatory News Service
Asieris: Cevira (APL-1702) NDA Advances to Second Round of Technical Review - A…
English 161.4 KB
2025-08-04 14:39
Regulatory News Service
Asieris: Cevira (APL-1702) NDA Advances to Second Round of Technical Review
English 4.1 KB
2025-07-22 08:00
Report Publication Announcement
Photocure ASA: Invitation to presentation of second quarter and first half year…
English 117.4 KB
2025-07-22 08:00
Report Publication Announcement
Photocure ASA: Invitation to presentation of second quarter and first half year…
English 2.5 KB
2025-06-23 14:55
Director's Dealing
Photocure ASA - Share option grant - Attachment: PHO_OSE_Primary_insider_notifi…
English 161.3 KB
2025-06-23 14:55
Remuneration Information
Photocure ASA - Share option grant - Attachment: Release.pdf
English 138.0 KB
2025-06-23 14:55
Remuneration Information
Photocure ASA - Share option grant
English 3.5 KB
2025-05-08 05:00
Investor Presentation
Photocure ASA: Results for the first quarter of 2025
English 1.2 MB
2025-05-08 05:00
Quarterly Report
Photocure ASA: Results for the first quarter of 2025
English 742.5 KB
2025-05-08 05:00
Earnings Release
Photocure ASA: Results for the first quarter of 2025
English 151.0 KB
2025-05-08 05:00
Earnings Release
Photocure ASA: Results for the first quarter of 2025
English 5.7 KB
2025-05-05 16:12
Post-Annual General Meeting Information
Photocure ASA: Annual general meeting held
English 439.1 KB

Automate Your Workflow. Get a real-time feed of all Photocure ASA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Photocure ASA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.